| mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
3e-07 |
| mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
2e-06 |
| mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
4e-06 |
| mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
5e-06 |
| mRNA |
navitoclax:PLX-4032 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
1e-05 |
| mRNA |
CCT036477 |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
1e-05 |
| mRNA |
ABT-263 |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
1e-05 |
| mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
2e-05 |
| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
3e-05 |
| mRNA |
vorinostat:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0002 |